Emil D. Kakkis - Oct 14, 2021 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
President & CEO, Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Oct 14, 2021
Transactions value $
-$69,093
Form type
4
Date filed
10/18/2021, 06:44 PM
Previous filing
May 10, 2021
Next filing
Feb 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Tax liability -$69.1K -853 -0.14% $81.00 594K Oct 14, 2021 Direct F1, F2
holding RARE Common Stock 2.26M Oct 14, 2021 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.